Phase 3 N=480 Combined Treatment for Mixed Incontinence
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: Change From Baseline UDI Total Score — -138.8; -142.7; -137; -147.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=123 Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women
Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 7.0; 9.8 score on a scale — p=0.001
Phase 4 N=88 The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence
Mixed Urinary Incontinence · Stress Urinary Incontinence · Urgency Incontinence
Primary: Number of Participants With Self-reported Mixed Urinary Incontinence Symptoms — 31; 34 Participants
N/A N=500 Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence
Urinary Incontinence
Primary: Percentage of Change From Baseline in 72-hour Incontinence Episode Frequency (IEF) Over Weeks 1-12 — -36.49; -37.83 percent change
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 3 N=150 Sling vs Botox for Mixed Incontinence
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: UDI-LF Total Score Change From Baseline — -82.2; -84.6; -74.9; -89.1 units on a scale
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
N/A N=61 Mindfulness + tDCS to Reduce Urgency Incontinence in Women
Urinary Incontinence, Urge
Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…
N/A N=64 Enhancing Conservative Treatment for Urge Incontinence
Urinary Incontinence
Primary: Change in Incontinent Episodes Immediately Post-treatment — -88.5; -78.3 percentage change — p=.16
N/A N=50 Continence Pessary Versus Disposable Intravaginal Device Trial
Female Stress Incontinence
Primary: Treatment Success — 8; 9 Participants
N/A N=400 Improving Care for Women With Urinary Incontinence (EMPOWER)
Urinary Incontinence
Primary: Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) — 8.4; 9.0; 9.9; 8.9…
N/A N=168 Trans-obturator Mid-urethral Sling and the Single-incision Sling in Women With Stress Urinary Incontinence
Urinary Incontinence, Stress
Primary: Percentage of Participants With Negative Cough Stress Test (CST) — 86.4; 83.1 percentage of participants
N/A N=70 The Urinary Incontinence Treatment Study
Urinary Incontinence · Sarcopenia
Primary: Number of Urinary Incontinence Episodes — 4.3; 2.7 number of incontinence episodes
Phase 4 N=645 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Frequency of Urge Urinary Incontinence Episodes at Week 12. — -2.5; -1.8 episodes — p=<0.001
Phase 4 N=28 Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
Multiple Sclerosis
Primary: Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Final Visit — 3.01; 2.56 score on a scale
N/A N=47 Dose-response of Physical Exercise on Pelvic Floor Muscle Function in Postmenopausal Women With Urinary Incontinence
Urinary Incontinence · Pelvic Floor Muscle Weakness
Primary: Pelvic Floor Muscle Function Measured by Digital Palpation — 4.00; 3.25; 3.75 score on a scale
N/A N=279 Improving Urinary Continence and Quality of Life in Prostate Cancer Patients
Urinary Incontinence
Primary: Amount of Urinary Leakage — 23.2; 22.3; 31.5; 11 grams
Phase 4 N=138 Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Urge Urinary Incontinence
Primary: Baseline Sexual Satisfaction Between Matched Female and Male Partners — 4.2; 4.8 score on a scale — p=.16
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Phase 4 N=168 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Urgency Urinary Incontinence
Primary: Responder (Yes/no) — 23; 39; 36; 17 Participants
N/A N=463 Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Urinary Incontinence, Stress · Urinary Incontinence, Urge
Primary: Group Behavioral Treatment Effectiveness as Shown by Changes From Baseline to 3 Months in Urinary Incontinence Severity. — -2; -1 units on a scale
N/A N=345 Bulking Agents for the Treatment of Stress Urinary Incontinence in Females
Stress Urinary Incontinence
Primary: Primary Effectiveness Endpoint — 107; 50 participants
N/A N=240 A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women
Stress Incontinence, Female · Stress Incontinence, Urinary · Stress Incontinence
Primary: Change From Baseline in Total Urinary Incontinence Episodes — -1.99; -1.7 episodes per day — p=0.056
Phase 4 N=395 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Bladder Outlet Obstruction
Primary: The Global Response Assessment (GRA) After the Treatment Day — 89; 218; 27; 61 participants
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
N/A N=208 Conservative Treatment of Postprostatectomy Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinence Episodes on Bladder Diary — 55; 51; 24 % change in episodes per week — p=.001
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day